10.54USD-3.04%Mkt Cap: 52.36M USDP/E: —Last update: 2026-05-26
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell ther…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap52.36M USD
Enterprise Value44.98M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-12.49M USD
Revenue/Share—
Last Price10.54 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees15
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.83
PEG—
EV/EBITDA-3.51
EV/Revenue—
P/S—
P/B-4.29
EPS (TTM)-2.80
EPS (Forward)-2.85
52W Range
6.8005% of range76.00
52W High76.00 USD
52W Low6.800 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE87.82%
ROA-87.75%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.93M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-9.83%
Net Debt-9.53M USD
Net Debt/EBITDA0.74
Balance Sheet
Debt/Equity-0.36
Current Ratio1.38
Quick Ratio1.31
Book Value/Sh-2.5530 USD
Cash/Share1.912 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateJan 28, 2025
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)39.00 USD
Target Range35.00 USD – 43.00 USD
# Analysts2
Ownership
Shares Out.4.98M
Float1.96M
Insiders60.47%
Institutions2.53%
Short Interest
Short Ratio1.7d
Short % Float3.99%
Short % Out.1.95%
Shares Short97.11K
Short (prev mo.)139.12K
Technical
SMA 5010.97 (-3.9%)
SMA 20012.43 (-15.2%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)43.12K
Avg Vol (10d)35.01K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—